Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-22-014629

EVP, Chief Dev. Officer sold 1,663 shares at $10.24 ($17,025)

  • EVP, Chief Dev. Officer acquired 68,250 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Frenkel Ran EVP, Chief Dev. Officer 2022-02-28 Grant or award +68,250 169,953 D
Frenkel Ran EVP, Chief Dev. Officer 2022-02-28 Sale −1,663 $10.24 $17,025 168,290 D
Derivatives
Frenkel Ran EVP, Chief Dev. Officer 2022-02-28 Grant or award · Stock Option (right to buy) +90,000 90,000 D
Open-market sales · 1,663 sh · avg $10.24 · $17,025
Loading xslF345X03/doc4.xml…